Group structure
6 companies in 2 countries
France3
United States1
Headquarters not stated2
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Loading…
6 companies in 2 countries
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Every medicine of every company in the group, current ones first.
11 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| AMPHADASE150 units/ml · Injectable | Hyaluronidase | United States | Marketed | 2004 |
| BAQSIMI3MG · Powder | Glucagon | United States | Marketed | 2019 |
| BAQSIMI3 mg / container · Powder | Glucagon | Canada | Marketed | 2019 |
| Baqsimi | Glucagon | EU (EMA) | Authorised | 2019 |
| BAQSIMI 3 MG POLVO NASAL EN ENVASE UNIDOSIS3 mg · Polvo nasal | Glucagon | Spain | Marketed | 2020 |
| Baqsimi 3 mg, snuifpoederSnuifpoeder | Glucagon | Netherlands | Authorised | 2019 |
| CORTROSYN0.25mg/vial · Injectable | Cosyntropin | United States | Marketed | 1970 |
| CORTROSYN INJ 0.25MG0.25 mg / vial · Powder For Solution | Tetracosactide | Canada | Marketed | 1974 |
| DUOCAINE0.375% (37.5mg/10ml); 1% (100mg/10ml) · Injectable | Bupivacaine, Lidocaine | United States | Not marketed | 2003 |
| ENOXAPARIN SODIUM (PRESERVATIVE FREE)100mg/ml (100mg/ml) | 120mg/0.8ml (150mg/ml) | 150mg/ml (150mg/ml) | 30mg/0.3ml (100mg/ml) | 40mg/0.4ml (100mg/ml) | 60mg/0.6ml (100mg/ml) | 80mg/0.8ml (100mg/ml) · Injectable | Enoxaparin | United States | Marketed | 2010 |
| REXTOVY4mg/spray · Spray, metered | Naloxone | United States | Marketed | 2023 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 6 | 6 | 0 | CompaniesAll medicines |
| Canada | 2 | 2 | 0 | CompaniesAll medicines |
| Spain | 1 | 1 | 0 | CompaniesAll medicines |
| European Union (EMA) | 1 | 1 | 0 | CompaniesAll medicines |
| Netherlands | 1 | 1 | 0 | CompaniesAll medicines |
Also in the registers of Brazil, France, Germany, Italy, Sweden
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Companies are grouped by Prognia from the names regulators publish; not an official corporate structure.
Source: European Medicines Agency (EPAR data).
Licence: EMA reuse policy (source acknowledgement required)
Fuente de la información: AEMPS (CIMA).
Licence: AEMPS open data reuse with attribution
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Source: BDPM (ANSM, HAS, UNCAM).
Licence: Licence Ouverte v1.0
Anvisa, official medicine/API manufacturer factual export, HTTP source version Fri, 09 Oct 2026 08:21:54 GMT, acquired 2026-10-09; exact unmodified native identifiers and fields preserved.
Licence: Brazil federal factual open-data reuse; Decreto 8777/2016 consolidated article 4 and third-party exceptions
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM), published shortage reports CSV, retrieved 2026-10-28.
Licence: commercial redistribution permission not established
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
BDPM / ANSM, HAS and UNCAM; original URLs and each update date retained
Licence: BDPM exact Licence Ouverte v1.0 (October 2011)
BDPM / ANSM, HAS and UNCAM, CIS_MITM.txt, published 13/10/2026, acquired 2026-10-25T22:15:46.803459+00:00; exact facts retained, no endorsement.
Licence: BDPM exact Licence Ouverte v1.0 (October 2011)
INSEE (www.insee.fr), via DINUM API Recherche d’entreprises; include original record update date and retrieval date
Licence: Licence Ouverte / Open Licence
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_A_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:41 GMT; acquired 2026-10-13T17:21:06.055244+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://drive.aifa.gov.it/farmaci/confezioni_fornitura.csv; HTTP Last-Modified Mon, 12 Oct 2026 23:02:44 GMT; acquired 2026-10-13T17:21:16.224007+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.
Licence: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim
Läkemedelsverket, Sweden, Förvaringstemperatur och hållbarhet, source extract 2026-10-20, acquired 2026-10-20T20:46:08.868635+00:00. Original cells retained; structured adaptation by Prognia. No regulator endorsement.
Licence: Creative Commons Attribution 4.0 International (CC BY 4.0)
Läkemedelsverket, Sweden, Läkemedelsprodukter, source extract 2026-10-20, acquired 2026-10-20T20:45:53.483733+00:00. Original cells retained; structured adaptation by Prognia. No regulator endorsement.
Licence: Creative Commons Attribution 4.0 International (CC BY 4.0)
FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.
Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions
Report an error or request removalCorrections from the company itself are welcome.
Keep Amphastar’s medicines accurate on Prognia, see how professionals use them and answer what they ask. A 20-minute call, in English.
Book a callWell-known pharmaceutical groups, each with all its companies.